How has Amneal Pharmaceuticals, Inc.'s specialty — cost of goods sold changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — cost of goods sold decreased by 13.5% year-over-year, from $55.8M to $48.27M.

What does specialty — cost of goods sold mean?

Includes all direct costs attributable to the production and manufacturing of specialty pharmaceutical products, such as raw materials, labor, and overhead. Monitoring this metric helps evaluate manufacturing efficiency and the direct cost burden of the segment's product portfolio.

Amneal Pharmaceuticals, Inc. (AMRX) Specialty — Cost of goods sold

Screener

Other segment segments

Affordable Medicines

$282.68M+11.9%

AvKARE

$130.74M+0.7%

Similar metrics at other companies

LKQSpecialty — Cost of goods sold

$310M+3.7%

DORMSpecialty Vehicle — Cost of goods sold

$25.86M+5.5%

IAR

IARTSpecialty Surgery — Cost of goods sold

$130.21M+8.3%

SCSCSpecialty Technology Solutions — Cost of goods sold

$659.34M+9.1%

AVN

AVNSTotal Specialty Nutrition Systems — Cost of goods sold

-$48M-36.4%

LULUProduct costs — Cost of goods sold

$746.45M+14.3%

Other financials

Income statement

See full

Revenue$796.2M+9.9%

Gross profit$334.5M+16.9%

Operating income$129.8M+16.5%

Net income$57.7M+157%

EPS (diluted)$0.18+157%

Balance sheet

See full

Cash & equivalents$127.6M+78.4%

Total debt$2.6B+18.0%

Total equity$33.0M+129%

Total assets$3.8B+10.3%

Cash flow

See full

Operating cash flow-$21.2M-125%

CapEx$30.7M+34.5%

Free cash flow-$51.9M-185%

Valuation

See full

Market cap$5.77B+129%

Enterprise value$8.21B+77.4%

P/E36.7×-711×

P/S1.9×+1.0×

Profitability

See full

Gross margin39.3%+1.7pp

Operating margin14.6%+1.4pp

Net margin5%+4.9pp

FCF margin4.1%-5.8pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity77.8×—

Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:19 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001723128-26-000031

Three Months Ended June 30, 2026	Affordable Medicines (1)	Specialty	Av KARE	Corporateand Other	Total Company
Net revenue	$489,913	$149,295	$156,989	—	$796,197
Cost of goods sold	282,684	48,265	130,740	—	461,689
Gross profit	207,229	101,030	26,249	—	334,508
Selling, general and administrative	42,367	40,095	16,913	49,347	148,722
Research and development	33,023	5,994	—	—	39,017
Intellectual property legal development expenses	2,002	85	—	—	2,087
Acquisition costs	—	—	—	7,600	7,600
Restructuring and other charges	—	—	—	554	554

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — cost of goods sold?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — cost of goods sold of $48.27M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — cost of goods sold changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — cost of goods sold decreased by 13.5% year-over-year, from $55.8M to $48.27M.
What does specialty — cost of goods sold mean?: Includes all direct costs attributable to the production and manufacturing of specialty pharmaceutical products, such as raw materials, labor, and overhead. Monitoring this metric helps evaluate manufacturing efficiency and the direct cost burden of the segment's product portfolio.